Michael Ackermann, Director at Tarsus Pharmaceuticals, Inc. (TARS), bought 100,000 shares at $13.50 ($1.4M) on 2022-05-05, disclosed to the SEC on 2022-05-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| TARS | SELL | 2021-10-14 | $267K | — | Filing → |
| TARS | SELL | 2021-10-12 | $5K | — | Filing → |
| TARS | SELL | 2021-09-03 | $294K | — | Filing → |